Highlighting the need for a therapeutic solution in Stress Urinary Incontinence during World Continence Week

/in

Optimum Strategic Communications is pleased to support Versameb during World Continence Week, a company raising awareness of the high unmet medical need of patients suffering with Stress Urinary Incontinence (SUI) and continence related issues which impacts the lives of millions of patients worldwide. Versameb’s Chief Executive Officer, Klaas Zuideveld to present on the Company’s proprietary […]

Read more

Ariceum Therapeutics Launches with €25M Series A

/in

Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News

Read more

Synklino’s Breakthrough Approach to Eliminate Transplant Related CMV

/in

Synklino, the emerging biotech company developing breakthrough drugs for the treatment of chronic viral infections, accelerates development of its drug candidate SYN002  for the treatment of Cytomegalovirus (CMV), into both ex vivo and in vivo Phase 1 clinical trials, following a Series A fundraise of EUR 29.8 million. PKA pension fund led the funding round, […]

Read more

ON Helix Digital Conference 2022

/in

Optimum supports One Nucleus’ flagship conference, ON Helix, which brings the network together to present and discuss the main innovation and technology trends in healthcare research and development. This one-day conference will address the main bio innovation trends, from the developments in life science and technology research to their translation into new diagnostics, prevention tools […]

Read more

Novo Ventures is ready for steady deployment of funds amid IPO lull

/in

Novo Ventures senior partner, Naveed Siddiqi, discussed the opportunity in a slumbering IPO market to raise larger funding rounds, in an interview with Unquote.

Read more